Dr. Doug Williamson

• 
  www.indystar.com/apps/pbcs.dll/section?Category=NEWS07 - [Cached Version]
  Published on: 2/19/2008    Last Visited: 2/26/2008  

  Dr. Doug Williamson, a research scientist at Eli Lilly and Co., says his native Scotland celebrates two big holidays a year: New Year's Eve and poet Robert Burns' birthday.

• 
  www.pharmabiz.com/article/detnews.asp?articleid=41839&s - [Cached Version]
  Last Visited: 12/4/2007  

  "Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," said Doug Williamson, M.D, Cymbalta associate medical director for Eli Lilly and Company.

• 
  jennersville.discoveryhospital.com/main.php?t=symptom&p - [Cached Version]
  Last Visited: 12/3/2007  

  "Relapse, the re,emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company.Read More ...

• 
  www.indystar.com/apps/pbcs.dll/article?AID=/20080203/CO - [Cached Version]
  Published on: 2/3/2008    Last Visited: 2/3/2008  

  Dr. Doug Williamson, a research scientist at Eli Lilly and Co., says his native Scotland celebrates two big holidays a year: New Year's Eve and poet Robert Burns' birthday.
  ...
  The fact that the two are separated by only a few weeks (Burns was born Jan. 25, 1759) can mean a lot of celebrating in a short span of time, but that didn't stop Williamson from donning his kilt last weekend for the annual Burns Supper.
  ...
  Williamson, who was born in Dumfries, Scotland, and worked summers helping his grandfather maintain the Robert Burns Museum, took part in some of the evening's formal activities along with his wife, Dr. Sara Corya.

• 
  www.theinsurancehelpline.co.uk/blog/depression-and-anxi - [Cached Version]
  Last Visited: 12/31/2007  

  "Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," observed Dr Doug Williamson, Cymbalta associate medical director for Eli Lilly.
  
  "This approval from the FDA is important because data from our Cymbalta clinical trial demonstrate that continuing to treat the patient delays the time to possible relapse," he continued.

• 
  www.kosmix.com/health/depression-s - [Cached Version]
  Last Visited: 12/1/2007  

  successful treatment of depression, is a significant clinical concern," says Doug Williamson, M.D.,, Cymbalta associate medical director for Eli ...

• 
  www.pmlive.com/pharm_market/earlier_news.cfm?showArticl - [Cached Version]
  Published on: 11/30/2007    Last Visited: 1/4/2008  

  Dr Doug Williamson, Cymbalta associate medical director for Lilly, said: "Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern.

• 
  Learning & Training Programs for Pharmaceutical... - [Cached Version]
  Published on: 1/20/2007    Last Visited: 12/4/2007  

  Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults. 'Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern,' says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company [Read More] Caraco Pharmaceutical Laboratories, Ltd.Announces Tentative FDA Approval for Generic Lexapro(R)

• 
  Mental Health News from Medical News Today >... - [Cached Version]
  Published on: 8/20/2006    Last Visited: 12/1/2007  

  "Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company. [click link for full article]Forest Laboratories, Inc.

• 
  PharmaLive: FDA Approves Cymbalta for Maintenance... - [Cached Version]
  Published on: 11/30/2007    Last Visited: 12/18/2007  

  "Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company.

Page:  1 2